IP Library Granted Patent US 7,238,176
Granted Patent B2
US 7,238,176 · App. 10/835,087 · Granted Jul 3, 2007

Method for intrastromal photodisruption of dome-shaped surfaces

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,238,176
App. No.
10/835,087
Granted
Jul 3, 2007
Kind
B2
Abstract

A method is disclosed for photodisrupting a surface in the stroma of an eye at a substantially constant distance from the anterior surface of the eye. A frame of reference is established for the eye that includes an axis of rotation. Next, the focal point of a laser beam is positioned in the stroma at a radial distance from the axis. At least one laser pulse is delivered to the stromal tissue at the focal point, photodisrupting the tissue there and creating a photodisruption bubble having a diameter “d”. The focal point is then rotated about the axis through an arc length substantially equal to “d” and the photodisruption step is repeated. During rotation, the distance between the focal point and the axis is decreased at a rate substantially equal to the distance “d” per revolution. The method can be used to create a flap for a LASIK type procedure.

Claims (38)

1. A method for photodisrupting a surface in the stroma of an eye, at a substantially constant distance from the anterior surface of the eye, the method comprising the steps of:

establishing a frame of reference for the eye, wherein the frame of reference includes an axis of rotation;

positioning the focal point of a laser beam in the stroma at a radial distance from the axis of rotation;

photodisrupting tissue at the focal point to create a bubble having a diameter “d”;

rotating the focal point about the axis of rotation through an arc length substantially equal to “d” to repeat the photodisrupting step; and

decreasing the distance of the focal point from the axis of rotation, at a rate substantially equal to the distance “d” per revolution, during the rotating step.

2. A method as recited in claim 1 further comprising the step of moving the focal point in a direction substantially parallel to the axis during the rotating step.

3. A method as recited in claim 2 wherein the rotating, decreasing and moving steps are accomplished using a laser scanner configured to contemporaneously scan a focal point in three mutually orthogonal directions.

4. A method as recited in claim 2 wherein the focal point is moved toward the anterior surface of the eye during the moving step.

5. A method as recited in claim 1 further comprising the steps of:

providing a contact lens formed with an anterior surface and a posterior surface, with the posterior surface having a radius of curvature, R; and

engaging the cornea with the contact lens to conform the anterior surface thereof with the posterior surface of the contact lens.

6. A method as recited in claim 5 wherein the radius of curvature, R, of the posterior surface of the contact lens is in a range of between approximately 7.5 mm and approximately 11.0 mm.

7. A method for moving a laser beam focal point within the cornea of an eye to photodisrupt a pre-selected volume of corneal tissue, wherein the cornea has an anterior surface, the method comprising the steps of:

providing a contact lens formed with an anterior surface and a posterior surface with the posterior surface having a radius of curvature, R;

engaging the contact lens with the cornea to conform the anterior surface thereof with the posterior surface of the contact lens;

identifying a set of coordinates for each of a plurality of locations within the cornea wherein a photodisruption at each location results in a photodisruption of the pre-selected volume

providing a laser system having a laser source, laser scanner and an optical element with a cutting lens;

generating a laser beam and sequentially directing the laser beam through the scanning system, the optical element and the contact lens to a focal point at one of the locations within the cornea;

calculating a sequence of laser scanner positions from input data for moving the focal point along a path within the cornea to photodisrupt corneal tissue at each of the identified coordinates, the input data including optical characteristics of the optical element for a plurality of beam paths therethrough; and

using the sequence of laser scanner positions to move the focal point of the laser beam along the path and photodisrupt the volume of tissue.

8. A method as recited in claim 7 wherein the pre-selected volume of corneal tissue is a substantially dome-shaped layer.

9. A method as recited in claim 7 wherein the optical element comprises a plurality of lenses arranged as a telescope.

10. A method as recited in claim 7 wherein the optical element comprises a mirror and a plurality of lenses arranged as a telescope.

11. A method as recited in claim 7 wherein the identifying step comprises the steps of:

creating a planar pattern of locations; and

transforming the planar pattern into a non-planar pattern to obtain the identified coordinates.

12. A method as recited in claim 11 wherein the planar pattern of locations is formed as a spiral.

13. A method as recited in claim 11 wherein the curvature, R, of the contact lens is used as an input to the transforming step.

14. A system for photodisrupting a surface in the stroma of an eye, at a substantially constant distance from the anterior surface of the eye, the eye establishing a frame of reference which includes an axis of rotation, the system comprising:

a contact lens formed with an anterior surface and a posterior surface, with the posterior surface having a radius of curvature, R, the contact lens for engaging the cornea to conform the anterior surface thereof with the posterior surface of the contact lens;

a means for positioning the focal point of a laser beam in the stroma at a radial distance from the axis of rotation;

a means for photodisrupting tissue at the focal point to create a bubble having a diameter “d”; and

a means for rotating the focal point about the axis of rotation through an arc length substantially equal to “d” while decreasing the distance of the focal point from the axis of rotation, at a rate substantially equal to the distance “d” per revolution.

15. A system as recited in claim 14 further comprising a means for moving the focal point in a direction substantially parallel to the axis during rotation of the focal point about the axis of rotation.

16. A system as recited in claim 15 wherein the rotating means and the moving means comprise a laser scanner configured to scan a focal point in three mutually orthogonal directions.

17. A system as recited in claim 14 wherein the moving means moves the focal point toward the anterior surface of the eye.

18. A system as recited in claim 14 wherein the radius of curvature, R, of the posterior surface of the contact lens is in a range of between approximately 7.5 mm and approximately 11.0 mm.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2009
From: 20/10 PERFECT VISION AG
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023510/0024 →
CHANGE OF NAME Recorded Aug 10, 2009
From: 20/10 PERFECT VISION OPERATIONS GMBH
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023065/0970 →
CHANGE OF NAME Recorded Aug 6, 2009
From: 20/10 PERFECT VISION AG
To: 20/10 PERFECT VISION OPERATIONS GMBH
Reel/Frame 023065/0012 →
CHANGE OF NAME Recorded Aug 5, 2009
From: 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
To: 20/10 PERFECT VISION AG
Reel/Frame 023056/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2004
From: LOESEL, FRIEDER; SAUTER, THOMAS
To: 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
Reel/Frame 015569/0473 →